Recursion Pharmaceuticals, Inc. (RXRX): Cash & Equivalents
$743.29M
As of 2025-12-31
$545.68M
As of 2026-06-30
+10.6%
3-year compound annual growth
+23.2%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $743.29M | +25.1% | 2026-02-25, Balance as of period end |
| 2024-12-31 | $594.35M | +51.8% | 2026-02-25, Balance as of period end |
| 2023-12-31 | $391.56M | -28.8% | 2025-02-28, Balance as of period end |
| 2022-12-31 | $549.91M | +92.9% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $285.12M | +8.8% | 2023-02-27, Balance as of period end |
| 2020-12-31 | $262.13M | n/a | 2022-03-23, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Recursion Pharmaceuticals, Inc. (RXRX) | 2025-12-31 | $743.29M | +25.1% |
| Autolus Therapeutics plc (AUTL) | 2025-12-31 | $104.13M | -54.2% |
| Compugen Ltd (CGEN) | 2025-12-31 | $90.60M | +397.0% |
| Black Diamond Therapeutics, Inc. (BDTX) | 2025-12-31 | $20.99M | -42.4% |
| Vir Biotechnology, Inc. (VIR) | 2025-12-31 | $232.19M | +4.1% |
| MeiraGTx Holdings plc (MGTX) | 2025-12-31 | $65.93M | -36.4% |
| 4D Molecular Therapeutics, Inc. (FDMT) | 2025-12-31 | $60.24M | -59.7% |
| Sutro Biopharma, Inc. (STRO) | 2025-12-31 | $58.13M | -69.5% |
| Invivyd, Inc. (IVVD) | 2025-12-31 | $226.69M | +226.9% |
Compare RXRX, AUTL, CGEN, BDTX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗